Xencor and Adlai Nortye add new oncology data as ESMO roundup widens

Xencor presented updated Phase 1 dose-expansion data for XmAb819, an ENPP3 x CD3 bispecific antibody, in advanced clear cell renal cell carcinoma on Oct. 26, 2026. At the 400 μg/kg target dose, confirmed ORR was 45.5% (16.8, 76.6) among 11 efficacy-evaluable patients, with disease control rate of 81.8%.¹ Across subgroups, the company reported consistent activity in patients with prior exposure to HIF2α inhibitors (cORR 34.8%) and in those with prior exposure to two or more VEGFR-TKIs (cORR 45.2%).¹ Xencor said it expects to have cash to fund research and development programs and operations into 2029.¹ The company also outlined plans for 2027, including initiation of the first registration-enabling study in ccRCC targeted by year-end 2027.¹

Separately, Adlai Nortye announced on Oct. 27, 2026 that an oral presentation on its AN4035 program will be shared during the 38th EORTC-NCI-AACR Symposium, taking place November 18-20 in Barcelona, Spain.² The company said the presentation will include translational and combination data supporting the ongoing Phase I study of AN4035, including its evaluation with EGFR blockade.² Adlai Nortye is evaluating AN4035 in patients with CEACAM5-enriched RAS-addicted solid tumors in a global Phase I trial in Australia, U.S., and China.²

These disclosures follow earlier ESMO 2026 updates from Nanobiotix on JNJ-1900 (NBTXR3) in melanoma, NovaBridge Biosciences on givastomig in gastroesophageal adenocarcinoma, and Eikon Therapeutics on EIK1001 in non-small cell lung cancer, all presented in Madrid between Oct. 24 and Oct. 26, 2026.